Message resonance gains ground as a practical measure of client confidence

Tern plc

Companies are placing greater weight on message resonance as a direct indicator of whether their communications are working. The focus is shifting away from volume-based metrics such as reach and impressions towards whether audiences actually understand and trust what is being said.

This change has clear implications for investors. Message resonance provides a more actionable signal of how well a company is positioned with its audience. Strong alignment between messaging and audience expectations can support client retention and reduce reputational risk, while weak resonance may point to gaps in strategy or execution.

The relevance of this metric is most evident in sectors where trust plays a central role. In regulated or complex markets, unclear or ineffective communication can undermine confidence and delay decision making. Companies that can demonstrate consistent, credible messaging are more likely to maintain stable relationships with clients and stakeholders.

From a commercial perspective, message resonance links communication directly to outcomes. It reflects whether messaging influences perception in a way that supports business objectives. This creates a clearer line between communication spend and return, which is increasingly important in tighter operating environments.

The measurement of message resonance typically combines multiple data sources, including audience behaviour and feedback across digital channels. This allows companies to adjust messaging quickly, improving effectiveness over time.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Search